Current understanding of tumor lysis syndrome
- 28 August 2019
- journal article
- review article
- Published by Wiley in Hematological Oncology
- Vol. 37 (5) , 537-547
Abstract
Tumor lysis syndrome (TLS) is an oncologic emergency from the intracellular release of material in lysing malignant cells. The earlier it is treated, the less likely it is to be harmful to an individual and spread through the body. Common complications of TLS include arrhythmias, which are caused by hypocalcemia or hyperkalemia, renal failures due to hyperuricemia or hyperphosphatemia, and seizures. Furthermore, the risk to develop TLS varies widely based on several factors including factors that are related to disease, the patient, and the treatment of the patient. Laboratory data can be used to gauge the severity of TLS based on patient serum levels for specific markers. On the contrary, evidence of TLS via radiological imaging and electrocardiogram findings has been a limited way to evaluate TLS, indicating the need for further research in this area. Common trends of treatment have also been seen in the past several years, evident by case studies seen in the following literature review.Keywords
This publication has 81 references indexed in Scilit:
- Spontaneous tumour lysis syndromeCanadian Medical Association Journal, 2012
- The Tumor Lysis SyndromeNew England Journal of Medicine, 2011
- Tumor Lysis Syndrome and Acute Kidney Injury: Evaluation, Prevention, and ManagementAmerican Journal of Kidney Diseases, 2010
- Sunitinib inducing tumor lysis syndrome in a patient treated for renal carcinomaInvestigational New Drugs, 2009
- Maxillary Sinus Squamous Cell Carcinoma Presenting with Fatal Tumor Lysis Syndrome: A Case Report and Review of the LiteratureCase Reports in Oncology, 2009
- Uric Acid and Cardiovascular RiskNew England Journal of Medicine, 2008
- Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock*Critical Care Medicine, 2006
- Tumour lysis syndrome: new therapeutic strategies and classificationBritish Journal of Haematology, 2004
- Efficacy and Safety of Rasburicase (recombinant urate oxidase) for the Prevention and Treatment of Hyperuricemia During Induction Chemotherapy of Aggressive Non-Hodgkin’s Lymphoma: Results of the GRAAL1 (Groupe d’Etude des Lymphomes de l’Adulte Trial on Rasburicase Activity in Adult Lymphoma) StudyJournal of Clinical Oncology, 2003
- Rapid tumour lysis syndrome in a metastatic colorectal cancer increased by treatment with irinotecan (CPT-11)European Journal of Cancer, 1996